REGENXBIO is a gene therapy company advancing a pipeline of treatments for rare and retinal diseases. The culture is purpose-driven and collaborative, with a focus on making a meaningful difference for patients and their families.
Own the overall rare disease franchise strategy, business performance, and P&L with full accountability for revenue, profitability, and commercial objectives.
Lead the commercial strategy and launch of RGX-202 while shaping the growth and evolution of the rare disease franchise.
Partner cross-functionally to turn strategy into execution and deliver meaningful outcomes for patients, providers, and the company.